Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · IEX Real-Time Price · USD

2.540

+0.180 (7.63%)

At close: May 6, 2024, 4:00 PM

2.660

+0.120 (4.72%)

Pre-market: May 7, 2024, 9:09 AM EDT

Lyell Immunopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-234.63	-183.12	-250.22	-208.05	-130.52
Depreciation & Amortization	20.25	18.02	13.62	4.29	1.26
Share-Based Compensation	47.08	81.92	62.2	33.26	15.73
Other Operating Activities	3.6	-86.38	48.15	6.04	151.86
Operating Cash Flow	-163.69	-169.56	-126.25	-160.87	39.47
Capital Expenditures	-2.69	-24.28	-65.5	-51.48	-16.05
Change in Investments	186.73	12.74	-56.07	-222.04	-406.39
Investing Cash Flow	184.05	-11.54	-121.57	-273.52	-422.43
Share Issuance / Repurchase	2.2	11.1	401.24	-11.43	-0.19
Other Financing Activities	-0.46	-0.46	-	488.22	351.34
Financing Cash Flow	1.74	10.64	401.24	476.79	351.16
Net Cash Flow	22.1	-170.46	153.42	42.4	-31.8
Free Cash Flow	-166.38	-193.83	-191.75	-212.36	23.43
Free Cash Flow Margin	-127984.62%	-228.89%	-1800.50%	-2737.94%	3565.75%
Free Cash Flow Per Share	-0.66	-0.78	-1.41	-16.02	4.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).